Floatz logo

hh160

Endometrial Cancer

Huahui HealthPhase 1Active
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

233 Active assets in the Endometrial Cancer cohort.

Asset / SponsorPhaseRating
Indocyanine Green
Istanbul University
Phase 4BB
Inno-206
AstraZeneca
Phase 3BB
Olaparib
Qilu Pharmaceutical Co., Ltd.
Phase 4BB
Palbociclib
University Medical Center Groningen
Phase 4BB
FILGRASTIM
Mayo Clinic
Phase 3B

View all 50 →

Same molecule, other indications

hh160 is also rated in:

small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
urothelial carcinomaDormant
C
Indicative ·
39 / 100
View asset →
gastroesophageal adenocarcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →